H
H1
Providing a trusted and single source of truth for healthcare professional information and the ecosystem in which they operate, will power connections in healthcare - and that these connections will…
About H1
H1.co is a healthcare technology startup that operates in the global healthcare and life sciences market. The company's primary mission is to connect the world with the right doctors and doctors to a world of research. It serves a diverse range of clients, including healthcare professionals (HCPs), life sciences companies, payors, providers, and patients.
H1.co's business model revolves around harnessing and democratizing healthcare data to inform decisions from bench to bedside. It provides data-validated insights to answer healthcare's most critical questions. The company's enterprise solutions include R&D Pipeline Acceleration, Clinical Trial Design, KOL Engagement, Education, and Market Access. These solutions are designed to increase the efficiency and effectiveness of healthcare delivery and research.
One of the key ways H1.co makes money is by providing AI-enabled data analytics and research to life sciences companies, HCPs, payors, and more. These services help clients discover strategic fits, increase their digital share of voice, and advance diversity in clinical trials. The company also offers a free-to-access platform for expert insights and opinions, H1 Connect, which keeps users up to date on the latest medical and life sciences research.
H1.co has a strong reputation in the industry, being trusted by over 250 leading companies. It prides itself on its data accuracy, breadth, and scale for every U.S. provider, which helps increase data coverage for provider affiliation, demographics, and patient coverage.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- New York City, United States
- Employees
- 546
- Open positions
- 22
- Dealroom signal
- 69.9/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Core AI, Data Platform, Tech for Biotech and Pharma, Tech for Hospitals and Clinics, Biotech and Pharma, AI Applications
- Technology
- Artificial Intelligence
- Business model
- Marketplace & ecommerce, SaaS
- Client focus
- b2b
- Investment activity
- 4 companies, latest Jun 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | May 2026 | $40M | $500M | CVS Health Ventures | ↗ |
| SERIES COther financing | Jun 2022 | $23M | $500M | Menlo Ventures · Novartis · Goldman Sachs Asset Management · Transformation Capital | ↗ |
Growth signals
Latest recorded traffic for H1 is 5.8K monthly website visits, down 88.4% over the last three months. H1's team grew 3.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
VEDA Data SolutionsMadison, United StatesVEDA creates fully automated data science and machine learning solutions to solve critical problems for health care payers and networks
$180Mvaluation
Ribbon HealthNew York City, United StatesEnterprise healthcare data platform for accurate & comprehensive info on doctors, insurance, and costs & quality of care
$174Mvaluation
Faculty OpinionsLondon, United Kingdom
→
CarevoyancePortland, United StatesCarevoyance - referral physician growth, health care market analysis, medical device sales intelligence
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Shore Group
Y Combinator
Series A6 investors entered at this stage
Menlo Ventures
IVP
Lux Capital
dRx Capital
Lead Edge Capital
Transformation Capital
Series B and later6 investors entered at this stage
Goldman Sachs
Altimeter Capital
Flex Capital
Novartis
Goldman Sachs Asset Management
CVS Health Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about H1 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See H1’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







